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Abstract
Background. – Sources of data used in France to routinely monitor vaccination coverage, such as the Child Health Certificates and school
surveys, allow reliable estimations, but data are not made available with long delays. To rapidly identify recent changes, we have explored the
feasibility and relevance of using vaccine reimbursement data.
Methods. – We used the Permanent Sample of Beneficiaries, a representative sample of the National Health Insurance Information System,
which contains data on health spending reimbursement of the vast majority of the population. We first validated this new source by comparing
measles vaccine coverage between Child Health Certificates and the Permanent Sample of Beneficiaries. We present herein the results on hepatitis
B, meningococcal C, and human papillomavirus vaccination (HPV) coverage.
Results. – Measles vaccine coverage estimated with the Permanent Sample of Beneficiaries (91.4%) is very close to the estimation obtained
through Child Health Certificates (90.6%). For children born in 2011, hepatitis B vaccination coverage at 24 months of age was 88.7% for one dose
and meningococcal vaccination coverage was 56.4% for one dose in December 2013. Of girls born in 1997, 20.1% had received the full HPV
vaccination series on their 16th birthday.
Conclusion. – This novel routine vaccination coverage monitoring tool provides regularly updated reactive and reliable vaccination coverage
estimates in children.
# 2015 Published by Elsevier Masson SAS.
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Re´sume´
Position du proble`me. – Les sources de donne´es utilise´es en routine pour estimer la couverture vaccinale en France, comme les certificats de
sante´ de l’enfant ou les enqueˆtes en milieu scolaire, permettent des estimations fiables mais sont peu re´actives. Nous avons donc explore´ la
faisabilite´ et la pertinence d’utiliser les donne´es de remboursement de vaccins pour estimer la couverture vaccinale, dans le but de pouvoir identifier
rapidement des changements re´cents.
Me´thodes. – Nous avons utilise´ l’e´chantillon ge´ne´raliste des be´ne´ficiaires, un e´chantillon repre´sentatif du syste`me national inter-re´gimes de
l’assurance maladie qui contient les donne´es de consommation de soins des assure´s sociaux. Nous avons d’abord valide´ cette nouvelle source de
donne´es en comparant la couverture vaccinale rougeole estime´e avec l’e´chantillon ge´ne´raliste des be´ne´ficiaires avec celle estime´e avec les
certificats de sante´. Nous pre´sentons ici les re´sultats des couvertures vaccinales he´patite B, me´ningocoque C et papillomavirus humain.
Re´sultats. – La couverture vaccinale rougeole estime´e avec l’e´chantillon ge´ne´raliste des be´ne´ficiaires e´tait tre`s proche (91,4 %) de celle
estime´e avec les certificats de sante´ (90,6 %). Parmi les enfants ne´s en 2011 la couverture vaccinale he´patite B (1 dose) e´tait de 88,7 % et la
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couverture vaccinale me´ningocoque C (1 dose) e´tait de 56,4 % a` 24 mois en de´cembre 2013. Concernant la vaccination contre le papillomavirus
humain, 20,1 % des jeunes filles ne´es en 1997 avaient rec¸u une vaccination comple`te a` l’aˆge de 16 ans.
Conclusion. – Ce nouvel outil, utilise´ maintenant en routine, permet de suivre les couvertures vaccinales des enfants de fac¸on fiable et re´active.
# 2015 Publie´ par Elsevier Masson SAS.
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Since 2004, the French Institute for Public Health
surveillance (InVS) has been in charge of monitoring
vaccination coverage. This requires reactive tools to assess
recent changes. This is particularly important in two types of
situation: after a modification in the immunization schedule
such as the introduction of a new vaccination or to assess the
impact of an event that can impact coverage positively (e.g., an
immunization campaign) or negatively (e.g., a vaccine scare).
Although immunization registries are regarded as one of the
best ways to assess vaccination coverage [1], this type of tool is
not available in France, and vaccinations given in private clinics
are not recorded in a central database. Vaccination coverage of
infants is routinely estimated by analyzing the information on
the immunization status recorded in the Child Health
Certificate (CHC) [2]. CHCs are filled in at 24 months for
all children by the medical practitioner following the child. In
older children, vaccination coverage is assessed through school
surveys conducted every 2 years alternatively at 6, 11, and
15 years of age [3–5]. Although these two sources of data
provide reliable results, their main limitation lies in their poor
reactiveness to changes in the immunization schedule. It takes
several years before the 24-month health certificate can
measure the vaccination coverage of a newly recommended
vaccination and the school surveys measure coverage of infant
vaccinations performed years before [6].
To generate more reactive data, we have explored the
feasibility and relevance of using vaccine reimbursement data
to closely monitor vaccination coverage.
2. Method
2.1. Source of data
In France, all vaccines included in the national immuniza-
tion schedule are reimbursed by the National Health Insurance
Scheme (NHIS). The NHIS is composed of several health
insurance plans and covers the entire French population. The
main health insurance system, the General Health Insurance
(GHI), is managed by the Health Insurance Fund for Salaried
Workers (CNAMTS) and covers approximately 77% of the
population residing in France [7]. The other major health
insurance systems are: the National Health Insurance Fund for
Agricultural Workers and Farmers (MSA), the National Health
Insurance Fund for the Self-employed (RSI), and special plans
covering students and civil servants (grouped in SLM),
covering approximatively 10% of the population. Parents canchoose to have their children vaccinated in either the private or
the public sector. About 85% of childhood vaccinations are
performed by the private sector. The vaccine is purchased at the
pharmacy under a prescription and is administered by the
physician. Most of the time, the vaccine is delivered free by the
pharmacist who is directly reimbursed by the client’s health
insurance. The reimbursement, made to either the pharmacist or
the client, is recorded, as is any other care act provided or
product delivered, in the database of his/her health insurance.
For children vaccinated in the public sector (about 15%),
according to the place or the type of vaccine, the vaccine is
either delivered free of charge by the Maternal and Child Health
(MCH) program or prescribed to be bought in a private
pharmacy. In the latter case, the same procedure as for vaccines
prescribed by private practitioners applies for vaccine reim-
bursement and registration in the client’s health insurance
database.
The databases of the different plans are progressively
merged into a single anonymous database, under the National
Health Insurance Inter-scheme Information System (SNIIR-
AM). It was created in 1999 in order to improve the knowledge
on use of care and the costs of health care consumptions. It
contains anonymous and comprehensive data on health
spending reimbursements from 2004 and for the entire
population covered by the health insurance system. The
database includes a large amount of information, among which
health care reimbursement data (including vaccine reimburse-
ments), data on patient characteristics (gender, date of birth,
place of residence, date of death, etc.), information about health
care workers, medical information (such as chronic disease
categories), and hospital admissions data. These data are stored
in a data warehouse for a period covering the current year plus
the 3 most recent years. Insured individuals who have had no
health consumptions during this period of time are not included
in the database. Up to 2012, access to this huge database was
restricted to the CNAMTS.
The need to monitor health care consumptions over more
than 3–4 years and to give access to a manageable database to
several public health institutions, including InVS, in 2005 led
the CNAMTS to establish a sample of the SNIIR-AM, the
Permanent Sample of Beneficiaries (EGB).
At that time, the EGB was a representative sample of 1/97th
of the health insurance beneficiaries covered by the GHI. It
includes about 500,000 individuals. In the first step, all GHI
beneficiaries with a strictly secret value of their National
Identity Register (NIR) control key number (going from 1 to
97) are selected and included in the EGB whether they have
consumed care or not. In a second step, the health care
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SNIIR-AM database and individually linked to each benefi-
ciary. Hence, the EGB database contains fully anonymized
individual data of a random selection of GHI health
beneficiaries, which will be followed for a period of at least
20 years. Health care consumptions have been integrated every
month since 2004 for the GHI. The time between actual
delivery of the vaccine by the pharmacist and availability of the
information in the EGB is 1 month [7,8].
We have explored the added value of the EGB to
complement classical sources of estimation of vaccine
coverage.
We present in this article the initial validation step conducted
by comparing measles, mumps, and rubella (MMR) vaccine
coverage between the EGB and the CHC. We then present data
on infant hepatitis B vaccination coverage for which dramatic
changes have recently occurred and on vaccination coverage of
two vaccinations recently introduced in the national immuniza-
tion schedule: the human papillomavirus vaccination (HPV) in
2007 and the anti-meningococcal C (Men C) vaccination in
2010.
2.2. Data analysis
2.2.1. Validation step with MMR vaccination data
The main challenge posed by the use of reimbursement data to
measurevaccine coverage in children was to account for vaccines
delivered free of charge in MCH clinics for which no
reimbursement information is available in the EGB. We therefore
had to find a way to exclude children receiving vaccine from the
MCH clinic stockpile from the denominators of our analysis. We
hypothesized that children in the EGB with no pentavalent or
hexavalent vaccine reimbursed in the 1st year of life were
children followed in MCH clinics. These children were excluded
from the denominators. To validate this hypothesis, we compared
MMR vaccine coverage estimates produced by the analysis of the
EGB under this hypothesis with estimates from CHC data. The
CHC data is the standard tool in France for the estimation of
vaccination coverage at the age of 2 years and its results have
been validated on several occasions through cross-checks with
population surveys [9,10]. The first dose of MMR vaccination is
scheduled at 12 months of age [11].
2.2.2. Analysis for meningococcal, hepatitis B, and HPV
vaccinations
We analyzed data until 31 December 2013. We estimated
vaccination coverage for children born between 2004 and 2011,
which allowed vaccination coverage estimations for children up
to the age of at least 24 months, even for the latest birth cohort.
According to the French childhood immunization schedule,
children are considered as correctly vaccinated for hepatitis B if
they received three doses at 24 months of age.
For the Men C vaccine, introduced in 2010, vaccination
coverage was only computed for children born in 2009 or after,
i.e., aged at least 12 months at the time the vaccination was
introduced. Current guidelines recommend one dose at
12 months of age.HPV vaccination has been recommended since 2007 for
girls aged 14 years, with a catch-up for girls aged 15–23 years
old who have had no sexual relationships or in the year
following the initiation of their sexual activity at the latest
[11]. We estimated HPV vaccination coverage for young girls
born between 1994 and 1998 at their 15th, 16th, and 17th
birthday. We were unable to estimate vaccination coverage after
the age of 17 years of age because at this age, many girls
become students and are no longer registered in the GHI. HPV
coverage was estimated for young girls present in the EGB
between 11 July 2007 (date of reimbursement of HPV vaccine)
and 31 December 2013.
Three doses given at least a 6 months between the first and
last dose are required for complete vaccination. For each
selected individual and vaccine, we extracted his or her vaccine
history (number of doses reimbursed and age at delivery). The
vaccination coverage, at a given age, was calculated by
dividing, for each vaccine and each dose (in case a series of
doses is needed for full vaccination), the number of vaccines
reimbursed by that age, by the number of eligible subjects of
that age in the EGB database.
3. Results
3.1. MMR
MMR vaccine coverage was estimated at 91.4% for one dose
at 24 months for the 2010 birth cohort. This figure is very close
to the 90.5% vaccination coverage estimated at 24 months for
the 2010 birth cohort, through the CHC [12]. We therefore
considered our methodology consisting in the exclusion of
children with no reimbursement of pentavalent or hexavalent
vaccines as valid and applied it for other childhood vaccinations
(except for Men C which was not delivered in MCH clinics at
the time of the analysis).
3.2. Hepatitis B
The latest figures show that 89.9% [95% CI: 88.8–91.0] of
children born in the first half of 2013 had started HBV
vaccination at the age of 6 months. Coverage at 6 months for at
least one dose was 30.7% [95% CI: 29.5–31.9] and 61.3% [95%
CI: 60.0–62.6], respectively, in the 2007 and 2008 birth cohorts
(Fig. 1). This increase was due to the eligibility for
reimbursement of the hepatitis B-containing hexavalent
vaccine in March 2008. At 2 years of age, vaccination coverage
was 67.2% [95% CI: 65.9–68.4] for the full three-dose
vaccination schedule, for the most recent birth cohort included
in the analysis (2011). This estimation was only 28.2% [95%
CI: 27.0–29.4] for the 2004 birth cohort (Table 1).
3.3. Meningococcal C
At the age of 24 months, 56.4% [55.2–57.6] of children
who were born in 2011 had been vaccinated with the Men C
vaccine; this figure was 48% for the 2009 birth cohort
(Table 1).
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
0  6  12  18  24  30  36  42  48  54  60  66  72  78  84  90  96 10 2 10 8 
VC
 
Age  in mon ths
Fig. 1. Cumulative vaccination coverage for one dose of hepatitis B vaccine
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The vaccine coverage for reception of at least one dose on
their 15th birthday has decreased from 23.1% [21.0–25.2] for
girls born in 1994 to 18.1% [16.7–19.5] for girls born in
1998. The vaccine coverage for reception of the full series on
their 16th birthday has decreased from 28.3% [26.0–30.6] for
girls born in 1994 to 20.1% [18.6–21.6] for girls born in 1997
(Table 2). These low HPV vaccination coverage rates improved
slightly through a limited catch-up between 16 and 17 years of
age (Table 2). However, the vaccine coverage reached in
2013 for girls born in 1996 at their 17th birthday (29.5%) was
lower than the level reached in 2012 for the girls born 1 year
before (31.2%) (Fig. 2).
4. Discussion
The use of reimbursement data is a new and relevant
approach to assess vaccination coverage in France, in that itTable 1
Hepatitis B vaccination and meningococcal C vaccination coverage at 24 months 
Year of birth 2004 2005 2006 2007 
n 5021 5258 5305 5275 
Hepatitis B vaccination coverage (%)
1 dose 41.9
[40.5–43.3]
44.8
[43.5–46.1]
46.8
[45.5–48.1]
52.8
[51.5–5
3 doses 28.2
[27.0–29.4]
30.2
[29.0–31.4]
32.3
[31.0–33.6]
37.0
[35.7–3
Meningococcal C vaccination coverage (%)
1 dose – – – – allows reactive and regularly updated vaccination coverage
estimations, including for vaccines newly introduced into the
immunization schedule for which the routine vaccination
coverage monitoring tools are not operational.
To our knowledge, except in Germany [13,14], reimburse-
ment data have never been used for the estimation of
vaccination coverage in other European countries [15].
These data are a less expensive and easier alternative to
specific surveys, which are very resource-consuming and difficult
to repeat regularly. For the Men C vaccine reimbursed by the
French Health Insurance in July 2010, coverage estimations were
already available at the beginning of 2011. Similarly, the EGB
already demonstrated an increase in hepatitis B vaccination
coverage by the end of 2008, a few months after the
reimbursement of the hexavalent vaccine by the French Health
Insurance scheme in March 2008. It also showed a small decrease
in HPV vaccination coverage in 2012 that occurred the same year.
One reason that could explain this decrease is the media attention
in two cases of neurological disorders which appeared shortly
after HPV vaccination in two teenage girls and were presented
as possible side effects of the vaccine.
Our EGB vaccination coverage estimates agree with the
other sources of data. An internet-based study conducted in
France in 2011 showed an 88.5% first-dose MMR coverage
between 12 and 23 months [16]. These results are consistent
with our 91.4% figure obtained through the EGB for the
2010 birth cohort at 24 months of age. The 56.4% vaccination
coverage for Men C for children born in 2011 at 24 months of
age is close to the coverage found in an internet-based study,
which showed a 32.3% coverage between 12 and 23 months of
age and a 57.3% coverage between 24 and 35 months of age
[17]. Both estimations show insufficient coverage in this age
group. Regarding HPV vaccination, our analysis showed a very
disappointing coverage with only 20.1% of the targeted girls
being vaccinated at 16 years of age in 2013. Our estimates are
consistent with a survey in which 23.6% of girls aged 15 years
in 2012 were fully immunized against HPV [18].
However, the use of EGB for the assessment of vaccination
coverage presents several limitations.
First, some vaccinations dispensed very early in life are not
recorded in the database. For the 2010 birth cohort, the hepatitis
B vaccination coverage estimated by the EGB and by health
certificates at 24 months of age were close for the first dose
(respectively, 85.6% and 84.7% [9]), whereas the third doseas of 31 December 2013, France.
2008 2009 2010 2011
5428 5479 5818 6106
4.1]
71.5
[70.3–72.7]
82.3
[81.3–83.3]
85.6
[84.7–86.5]
88.7
[87.9–89.5]
8.3]
52.2
[50.9–53.5]
58.4
[57.1–59.7]
61.2
[59.9–62.5]
67.2
[65.9–68.4]
– 48.0
[46.7–49.3]
54.1
[52.8–55.4]
56.4
[55.2–57.6]
Table 2
HPV vaccination coverage as of 31 December 2013. France.
Year of birth 1994 1995 1996 1997 1998
n 1486 1844 2736 2876 2746
1 dose at 15 years of age 23.1%
[21.0–25.2]
23.6%
[21.7–25.5]
26.3%
[24.7–27.9]
19.6%
[18.1–21.1]
18.1%
[16.7–19.5]
3 doses at 16 years of age 28.3%
[26.0–30.6]
26.9%
[24.9–28.2]
26.4%
[24.7–28.1]
20.1%
[18.6–21.6]
–
3 doses at 17 years of age 33.0%
[30.6–35.4]
31.2%
[29.1–33.3]
29.5%
[27.8–31.2]
– –
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(78.1%). Our data showed that, on the one hand, the average age
at the first dose was 2.2 months in children who received at least
three hepatitis B vaccine reimbursements and 4.5 months (close
to the age of the second dose) in children who received only two
reimbursements. Furthermore, 39.9% of second doses in
children who received only two reimbursements were delivered
between 15 and 19 months of age, which is the age of the third
dose. This strongly suggests that, in some children, the first
dose recorded in the database is the actual second dose and the
second dose is the third one. This is very likely the consequence
of the late registration of infants in the SNIIR-AM, which failed
to capture the reimbursement of the first dose scheduled at
2 months of age. Contacts with the CNAMTS, which manages
the EGB database, have confirmed our finding of uncompleted
recording of care given in the very first weeks of life. Another
potential contributing explanation would be that some of these
infants received the first dose in an MCH clinic, free of charge,
and the subsequent ones in the private sector.
Second, this study focused on the beneficiaries of the GHI,
which covers only 77% of the population, and no data exist
comparing the prevention attitudes of the population according to
their insurance coverage. This limitation will soon be overcome
in 2011, when the EGB database is loaded with the beneficiaries
of the two other important health insurance plans, MSA and RSI.0% 
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Fig. 2. Cumulative vaccination coverage for three doses of HPV vaccine
according to age and year of birth, France.
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civil servants (SLM) are currently being added, which will
expand the EGB coverage well above 95% of the population in
the very near future. More importantly, in 2012, InVS was
granted access to the comprehensive SNIIR-AM database of
reimbursement for all medical care of all of France’s 64 million
residents. Besides covering the whole population, this compre-
hensive database will allow the analysis of data at the subnational
level (region, district, and even subdistrict). This type of analysis,
which is impossible through the EGB due to an insufficient
sample size, will allow identifying pockets of undervaccinated
populations at a small geographical scale and planning
complementary vaccination activities targeted to those specific
subpopulations. The relevance and feasibility of using this huge
database for vaccine coverage monitoring is currently being
explored by InVS, as part of its mandate of vaccine coverage
monitoring in France.
A third limitation of the EGB is that it only covers persons for
whom the GHI pays for the vaccines. The inclusion in the
denominator of children vaccinated in the public sector with free
delivery of the vaccine would tend to underestimate the coverage.
We therefore restricted the analysis to children for whom at least
one dose of pentavalent or hexavalent vaccine had been
reimbursed during the 1st year of life. We therefore excluded
from the calculation fully unvaccinated children. We believe the
resulting bias to be very low given that these combined vaccines
include mandatory diphtheria, tetanus, and polio vaccinations for
which coverage is estimated to be above 98% [12]. However, this
restriction of the denominator led to the exclusion of about 10%
of children, either followed in MCH clinics that still buy their
own vaccines or those having been vaccinated through the small
vaccine stockpile kept in all MCH clinics, mainly for children
with no or incomplete health insurance coverage. This restriction
may also have underestimated the vaccination coverage since
children who were vaccinated partly in the public sector and
partly in the private sector remain in the analysis. On the other
hand, having excluded those children with one or two pentavalent
or hexavalent vaccines reimbursed in the 1st year of life would
have overestimated the vaccination coverage, because many of
them are actually partially vaccinated. Indeed, a similar
calculation made for MMR vaccination coverage yielded a
vaccine coverage of 93.7%, higher than the health certificate
estimation (90.6%), whereas exclusion from the denominator of
children with no pentavalent or hexavalent vaccine reimburse-
ment yielded a vaccine coverage of 91.4%, much closer to the
estimation based on health certificates.
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the analysis of vaccination coverage in adults, because many
vaccinations are provided outside the private sector (by
occupational health services, public clinics, or travel medicine
clinics) without registration in the reimbursement databases.
In summary, the analysis made from the EGB cannot yet
fully estimate coverage of all children because it does not
include all health insurance plans or the small proportion of
children for whom vaccines are offered free of charge in MCH
clinics. However, the similarity of the results obtained from the
health certificates, the population-based surveys, and the EGB
lead us to believe that the EGB estimates are reliable and
provide reactive estimates. This will be even more true in the
near future because most of the limitations of the EGB will be
overcome. First, the EGB will soon encompass all health
insurance plans, which cover virtually the whole population.
Second, the proportion of children for whom vaccines are
provided free in the MCH will decrease even further with the
last MCH clinics adopting the common procedure of
prescribing vaccines for the vast majority of children.
Other limitations that may introduce some degree of bias and
affect the precision of the estimates calculated are the fact that
vaccines purchased are not necessary administered or that some
persons may purchase their vaccine without claiming reim-
bursement. There are no data to support these hypotheses or to
estimate the frequency of such situations, but we believe that
they are very rare. Finally, there may be a delay of several
weeks before the purchase and the actual administration of the
vaccine, but this should not affect the results as long as this
delay does not vary over time.
In conclusion, the EGB, and in the near future the whole
SNIIR-AM database, are novel and useful tools for routine
monitoring of vaccination coverage for vaccination in children
and adolescents, particularly because of its high reactivity after
changes in the vaccination schedule. It provides a rapid and
reliable estimate of vaccine coverage for new vaccines or after a
change in vaccine recommendation or implementation. Most of
the limitations underlined above should be overcome or greatly
reduced in the coming years.
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